In this roundtable discussion focused on the "Extended-Release (ER) Viloxazine Compared With Atomoxetine for Attention-Deficit/Hyperactivity Disorder (ADHD)" study published in July 2023 in volume 37 of CNS Drugs, experts Dr Gregory Mattingly, Dr Richard Price, and Dr Birgit Amann examine the evolving ADHD treatment landscape. They compare viloxazine ER with atomoxetine, offering insights into a range of current treatments, which include both psychostimulants and nonstimulants.